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Background and purpose — Medical treatment of rheumatoid 
arthritis (RA) has changed dramatically over the last 15 years, 
including immune modulation. We investigated the risk of revi-
sion for infection after primary total hip replacement (THR) in 
patients with rheumatoid arthritis over a 16-year period, and 
compared it with that in THR patients with osteoarthritis (OA).       
Patients and methods — We identified 13,384 THRs in RA 
patients and 377,287 THRs in OA patients from 1995 through 
2010 in a dataset from the Nordic Arthroplasty Register Asso-
ciation (NARA). Kaplan-Meier survival curves, with revision for 
infection as the endpoint, were constructed. Cox regression analy-
ses were performed to calculate the relative risk (RR) of revision 
for infection adjusted for age, sex, fixation technique, and year of 
primary surgery.
Results — RA patients had a 1.3 times (95% CI 1.0–1.6) higher 
risk of revision for infection. After 2001, this risk increased more 
for RA patients than for OA patients. During the first 3 months 
and from 8 years postoperatively, the risk of revision for infec-
tion was higher in RA patients with THRs fixated with antibiotic-
loaded cement than in corresponding OA patients.
Interpretation — We found a slightly higher overall risk of 
revision for infection in RA patients than in OA patients, but this 
difference was only present after 2001. In THRs with antibiotic-
loaded cement, the risk of very early and late infections leading to 
revision was higher in RA patients than in OA patients. 

Rheumatoid arthritis (RA) patients are particularly vulnerable 
to infections due to the nature of the disease (immunopathy 
and ongoing inflammation), general disability, comorbidity, 
and medication (Mutru et al. 1985, Doran et al. 2002). The 
increasing use of immune-modulating agents, particularly 
biologics, in the treatment of RA during the last decade may 
increase this risk of infection (Bongartz et al. 2006, Winthrop 
et al. 2008, Komano et al. 2011). RA often leads to joint 
destruction, so patients with RA are at risk of requiring joint 
replacement surgery. Before biologics were used, around 25% 
of all RA patients with 16–20 years of observation needed 
at least 1 large joint replacement (Wolfe and Zwillich 1998, 
Kapetanovic et al. 2008). Around 2–3% of all total hip replace-
ments (THRs) in the Nordic Arthroplasty Register Association 
(NARA) dataset have been performed on RA patients (Hav-
elin et al. 2009, Makela et al. 2014b).
The frequency of prosthetic joint infection is reported to be 
as low as 1–2% after hip or knee replacement (Zimmerli et al. 
2004), and the frequency of surgical revision due to infection 
is even lower (Pedersen et al. 2010, Schrama et al. 2010, Dale 
et al. 2012). In a previous study of RA patients with THRs 
from the Norwegian Arthroplasty Register, the risk of revision 
for infection was similar to that in osteoarthritis (OA) patients 
within 6 years of primary THR, whereas there was a higher 
risk of revision for infection in RA patients than in patients 
with OA from 6 years postoperatively. The overall risk of revi-
sion for infection was not significantly different in the 2 diag-
nostic groups (Schrama et al. 2010).
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Knowing that treatments for RA patients have improved 
dramatically in the last 10–15 years, we found it important to 
assess whether there is increased infection risk, which would 
require a large patient population to be followed over a long 
period. The collaboration between the Nordic arthroplasty 
registers—in the form of the NARA—has resulted in a large 
dataset on THR (Havelin et al. 2009, Makela et al. 2014a). 
This dataset gives the opportunity to study rare events in 
selected patient groups, such as revision due to infection after 
THR in patients with RA.
Based on what we know about increased infection risk 
associated with immunosuppressive treatments in general, we 
hypothesize that the new aggressive treatment strategies for 
RA that have evolved over the last decades including higher 
doses (e.g. of methotrexate), frequent use of combination 
regimes (e.g. methotrexate, hydroxochloroquine, and sul-
fasalazine), and the use of biologics, may make the patients 
more susceptible to infections—in this case, prosthesis infec-
tions.  
The main objective of our study was therefore to esti-
mate the risk of revision for infection after primary THR in 
RA patients relative to that in patients with OA, to evaluate 
whether today’s RA patients are at greater risk of prosthesis 
infection. We also wanted to evaluate risk factors for revision 
because of infection and to study the effect of the length of 
time from primary THR to revision. 
Patients and methods
The Danish Hip Arthroplasty Register was established in 1995 
(Lucht 2000), the Finnish Hip Arthroplasty Register in 1980 
(Paavolainen et al. 1991), the Norwegian Hip Arthroplasty 
Register in 1987, and the Swedish Hip Arthroplasty Register 
in 1979 (Havelin et al. 2000, Malchau et al. 2002). Denmark, 
Finland, Norway, and Sweden (with 25 million inhabitants) 
have similar healthcare systems, personal identity numbers, 
and census registries. This enables combination and compari-
son of the arthroplasty registries. The collaboration between 
the registries, the NARA, was established in 2007 (Havelin 
et al. 2009, Makela et al. 2014a). For the present study, we 
defined a common set of parameters containing only data that 
all the registries could provide, and we reached a consensus on 
the definition of several variables. In all the registries, report-
ing of infection as the cause of revision reflects the surgeon’s 
opinion based on clinical information and findings at surgery. 
The data are not edited according to postoperative culture 
results. From 1995 through 2010, a total of 390,671 primary 
THRs with the diagnoses RA or OA were identified in the 
NARA and included in the study (Table 1). Bilateral THRs 
were treated as 2 independent observations, since bilaterality 
has been shown to have a negligible influence on the risk of 
revision for infection (Lie et al. 2004, Ranstam and Roberts-
son 2010, Dale et al. 2012). The primary outcome measure 
was revision for infection following primary THR and only 
infections leading to revision of the prosthesis (removal or 
exchange of prosthetic parts) were included, since minor soft-
tissue procedures were not reported to all national registries.       
Firstly, we compared the overall risk of revision for infec-
tion after primary THR in patients with RA to that in patients 
with OA during 1995–2010 (Figure 1). We then evaluated 
the potential influence of biologics on the infection risk in 
patients with RA. Since we had no data on drug use in these 
patients, the risk of revision for infection was analyzed in 2 
different time periods: from 1995 to 2001, and from 2002 to 
2010. TNF-α inhibitors were introduced as treatment for RA 
in a few patients in Denmark, Finland, Norway, and Sweden 
in 1999–2000 (Hjardem et al. 2005, Nordstrom et al. 2006, 
Soderlin and Geborek 2008). From 2000, the use of TNF-α 
inhibitors increased steadily (Hjardem et al. 2005, Soderlin 
and Geborek 2008). Using 2001 as the cutoff, we attempted 
to divide the patients into 1 group (n = 6,337) (2002–2010) 
in which a considerable proportion of RA patients (20–30%) 
(Kvien et al. 2005) received treatment with biologics and 1 
group (n = 7,047) (1995–2001) in which few or no RA patients 
had such treatment. RA and OA patients were compared in the 
2 time periods, and the risk of revision for infection in the 2 
diagnostic groups was compared in order to evaluate the pos-
sible influence of important changes in medical treatment in 
the second time period. Finally, separate analyses were per-
formed for evaluation of the prosthetic fixation method on 
revision rate. 
Statistics
Survival analyses with revision for infection as the end point 
were performed for the total study population and for the 
THRs in RA patients and OA patients separately. Revision of 
the implant was defined as surgical removal or exchange of the 
whole or any part of the implant. Follow-up time was calcu-
lated from primary THR until first revision for infection, until 
the patient was censored at death or emigration, until date of 
table 1.  Patient characteristics
 RA OA p-value
No. of THRs 13,384 377,287 
Mean age (SD), years 62 (14) 69 (9.6) < 0.001
% females 76% 60% < 0.001
No. of primary THRs     < 0.001 
 1995–2001 7,047 130,613 
 2002–2010 6,337 246,674 
Type of fixation, n (%)        0.3         
 Cemented 8,633 (65) 245,464 (65) 
 Uncemented 3,034 (23)   83,547 (22) 
 Hybrid a 1,143 (8.5)   31,619 (8.4) 
 Inverse hybrid    574 (4.3)   16,657 (4.4)
Mean follow-up (SD), years     7.0 (4.3)         6.1 (4.1) < 0.001
a Hybrid: cemented stem and uncemented cup.
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revision if the THR was revised for other causes than infec-
tion, or until the end of the period studied on December 31, 
2010. Survival curves were generated using the Kaplan-Meier 
method. Cox regression analyses were performed to estimate 
the relative risk (RR with 95% CI) of revision for infection 
adjusted for age (continuous), sex, year of primary surgery, 
and method of fixation (Table 2). The RR is an estimate of 
the relative difference in revision risk between the groups at 
any given time throughout the observation period, and all RRs 
given are adjusted estimates. We chose to adjust for age as a 
continuous variable as opposed to performing stratified analy-
ses for age categories, due to the low number of events in the 
RA population. Additional Schoenfeld residual analyses were 
performed to detect any changes in revision risk with increas-
ing time since the primary surgery, in uncemented THRs, and 
where antibiotic-loaded cement was used—comparing RA and 
OA patients (Figure 3). The hybrids and reverse hybrids were 
included in these analyses together with the fully cemented 
prostheses in the antibiotic-loaded cement group. Adjusted 
RR estimates were further established for predefined follow-
up intervals, i.e. the first 3 months, 3 months to 2 years, 2 to 8 
years, and longer than 8 years, using an extended Cox model 
including time-dependent covariates. This largely follows the 
widely used Coventry prosthetic joint infection classifica-
tion into early infections (< 3 months), delayed infections (3 
months to 2 years), and late infections (> 2 years) (Coventry 
1975). The cutoff at 8 years was based on examination of the 
course of the curve in Figure 3B. Any p-values of 0.05 or less 
were considered to be statistically significant. The statistical 
analysis was performed using SPSS version 20.0 and the R 
statistical software package, version 3.0.2. 
Results
Patients with OA were generally older than the RA patients. 
We found no important difference in mean age in the 2 diag-
nostic groups when comparing the 2 time periods (mean age 
for RA patients was 61 years in the first period and 62 years in 
the second, and in OA patients it was unchanged at 69 years). 
We found no influence of increasing age on the risk of revision 
for infection (Table 2).
Overall results for RA and OA patients
Of the 390,671 THRs included (377,287 in the OA group and 
13,384 in the RA group), 2,315 were revised for infection. 
Of these revisions, 2,228 were in OA patients and 87 were in 
RA patients. The incidence of revision for infection was 0.6% 
in OA patients and 0.7% in RA patients. The overall risk of 
revision for infection was higher in RA patients than in OA 
patients (RR = 1.3, 95% CI: 1.0–1.6) (Table 2 and Figure 1). 
Men had a statistically significantly higher risk of revision for 
infection than women (RR = 1.9, CI: 1.8–2.1). 
Infection risk associated with RA according to time of 
primary surgery
For all patients and in both groups (RA and OA), the risk of 
revision for infection in the second period (2002–2010) was 
statistically significantly higher than in the first period (1995–
2001) (RR = 1.4, CI: 1.3–1.6) (Table 2 and Figure 2). For 
both diagnoses, this increase in infection risk was significant. 
In the first period, the risk of revision for infection was no 
higher for RA patients than for OA patients (RR = 1.1, CI: 
0.8–1.5) (Figure 2 and Table 3) whereas in the second period, 
RA patients had a higher risk of revision for infection than OA 
patients (RR = 1.4, CI: 1.0–1.8) (Figure 2 and Table 3). 
table 2.  Relative risk of revision for infection according to sex, age, 
diagnosis, year of surgery, and type of fixation, calculated using 
Cox regression analysis 
 No. of revisions RR 95% CI p-value
Age 2,315 1.0 0.99–1.01 0.1
Sex 
 Female 1,044 1 (ref.)  
 Male 1,271 1.9 1.8–2.1 < 0.001
Diagnosis 
 OA 2,228 1 (ref.)  
 RA 87 1.3 1.0–1.6 0.04
Year of primary surgery 
 1995–2001 858 1 (ref.)  
 2002–2010 1,457 1.4 1.3–1.5 < 0.001
Fixation 
 AB+ cement a 1,632 1 (ref.)  
 Uncemented 490 0.9 0.8–1.0 0.1
 AB– cement a 193 1.4 1.2–1.6 < 0.001
a AB+ cement: antibiotic-loaded cement. AB– cement: cement with-
out antibiotics.
Figure 1. Kaplan-Meier failure curves with revision for infection as the 
endpoint for rheumatoid arthritis (RA) and osteoarthritis (OA) patients. 
D
ow
nl
oa
de
d 
by
 [U
niv
ers
ite
tsb
ibl
iot
ek
et 
i B
erg
en
] a
t 0
1:3
8 3
0 D
ec
em
be
r 2
01
5 
494 Acta Orthopaedica 2015; 86 (4): 491–497
Effect of mode of fixation
There was no difference in frequency between the RA group 
and the OA group in terms of method of implant fixation 
(cemented, hybrid, or cementless) (Table 1). A higher risk of 
revision for infection was seen in THRs where cement with-
out antibiotics was used than in THRs with antibiotic-loaded 
cement (RR = 1.4, CI: 1.2–1.6) (Table 2). Additional analysis 
also revealed a higher risk of revision for infection in THRs 
with cement without antibiotics than in uncemented THRs 
(RR = 1.5, CI: 1.2–1.8).
Adjusted RR estimates for predefined follow-up intervals 
revealed a trend of a higher risk of revision in the RA group 
than in the OA group for uncemented THRs, throughout the 
study period (Figure 3A). For the antibiotic-loaded cement 
group, a higher relative risk of revision for infection was 
found for RA patients than for OA patients during the first 3 
postoperative months (RR = 1.8, CI: 1.1–3.0; p = 0.01), and 
after 8 years (RR = 2.7, CI: 1.2–6.3; p = 0.02) (Figure 3B).
discussion
We found an increased risk of revision for infection in RA 
patients than in OA patients. This was not found in a previous 
publication from the Norwegian Arthroplasty Register (Sch-
rama et al. 2010). In that study, the RA population was con-
siderably smaller (n = 4,167, with only 25 patients revised for 
infection). However, the current finding has been confirmed 
in other publications (Fitzgerald et al. 1977, Poss et al. 1984, 
Bongartz et al. 2008). Furthermore, in a previous study, total 
knee replacements (TKRs) were included in addition to THRs 
and a higher risk of revision of TKRs for infection was seen in 
RA patients than in OA patients (Schrama et al. 2010). 
Another finding was the increased risk of revision for infec-
tion from the first to the second time period in both patient 
groups. This has also been shown and discussed in a recent 
paper on infection in THRs from the NARA dataset by Dale 
et al. (2012).   
More revisions for infection in RA patients in 2002–2010
We found that the difference in risk of revision for infection 
between RA and OA patients emerged after 2002; no dif-
ference was seen in the period 1995–2001. A move towards 
accepting patients with more comorbidity for THR surgery 
may have taken place during the study period, but we have 
little reason to believe that this would have occurred to a 
greater extent in the RA population than in the OA popula-
Figure 2. Kaplan-Meier failure curves for rheumatoid arthritis 
(RA) and osteoarthritis (OA) patients in the periods 1995–
2001 and 2002–2010 with revision for infection as the end-
point.
table 3. Relative risk of revision for infection according to age, sex, 
and type of fixation for both diagnoses and time periods, calculated 
using Cox regression analysis
 No. of revisions RR 95% CI p-value
RA 1995–2001 44 1 (ref.)  
RA 2002–2010 43 1.9 1.2–3.1 0.006
OA 1995–2001 814 1 (ref.)  
OA 2002–2010 1,414 1.4 1.3–1.5 < 0.001
OA 1995–2001 814 1 (ref.)  
RA 1995–2001 44 1.1 0.8–1.5 0.5
OA 2002–2010 1,414 1 (ref.)  
RA 2002–2010 43 1.4  1.0–1.8 0.05
Figure 3. Log relative risk (RR) estimates of revision for infection in patients with 
rheumatoid arthritis (solid line) vs. osteoarthritis (0-line, reference) are shown by 
year after the primary surgery. Broken lines show the 95% confidence intervals. 
A. Uncemented total hip replacements with 22 revisions for infection in RA. 
B. Total hip replacements with antibiotic-loaded cement as fixation and 55 
 revisions for infection in RA.
A B
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tion. However, joint replacement surgery in RA patients has 
declined during recent years (Fevang et al. 2007, Jamsen et al. 
2013), and those still needing surgery would be patients with 
a long disease duration or non-responders to treatment, who 
may have particularly high disease activity. The latter group 
would have an increased risk of infection in general (Au et 
al. 2011), due to ongoing inflammation. Furthermore, the use 
of steroids would probably be greater in this group, possibly 
contributing to the increased infection risk (Akkara Veetil and 
Bongartz 2012). Another possible reason for the increased risk 
of revision for infection in RA patients in the latter period is 
the use of immune-modulating biologic drugs, although stud-
ies on the impact of these drugs in the context of joint replace-
ment surgery have so far been conflicting (Talwalkar et al. 
2005, Wendling et al. 2005, Giles et al. 2006, den Broeder 
et al. 2007, Ruyssen-Witrand et al. 2007, Gilson et al. 2010, 
Kawakami et al. 2010, Momohara et al. 2011, Suzuki et al. 
2011, Berthold et al. 2013). 
A change in strategy in treatment of RA with early intensive 
treatment aimed at remission was adopted during the last study 
period (Smolen et al. 2010a, Vermeer et al. 2011). Superior 
results have been shown with this strategy, but patients gener-
ally use higher doses of methotrexate and are often on combi-
nation regimes (with or without biologics and/or steroids). This 
might have led to greater impairment of the immune system, 
making patients more susceptible to prosthetic joint infection. 
A 40% increase in risk of revision for infection in RA 
patients relative to OA patients (RR = 1.4, Table 3) in 2002–
2010 of an already uncommon outcome (0.6% revision for 
infection in our study) still makes the absolute risk low. 
Many factors that influenced the risk of infection leading 
to revision (treatment policy, operating technique, diagnostics, 
awareness, etc.) may have changed with time. The possible 
changes in these factors are unlikely to have differed between 
RA and OA patients undergoing THR. By comparing RA 
patients with the large OA group, we tried to control for these 
factors when evaluating the risk of revision for infection in 
the 2 time periods. We studied the possible influence of the 
changed medical treatment of RA over time on the risk of revi-
sion for infection.
Effect of mode of fixation
Another finding of this study was that in RA patients with 
antibiotic-loaded cement, no difference in revision risk was 
seen compared to OA patients (except for the first 3 months), 
until an increased risk was evident in RA patients from 8 years 
postoperatively (Figure 3B). It appears that the antibiotics pro-
tected the THRs in RA patients against infection during the 
period from 3 months to 8 years postoperatively, although we 
cannot explain why this would not also be the case during the 
first 3 months. Our results concur with the findings of Josefs-
son and Kolmert (1993) that gentamicin-loaded cement is 
effective in infection prophylaxis for longer than 5 years but 
shorter than 10 years postoperatively.                                                            
After 8 years, the risk of revision for infection increased in 
the RA patients, probably because of the higher susceptibil-
ity to blood-borne infections connected to the diagnosis and 
possibly due to the immune-modulating medical treatment 
(Stinchfield et al. 1980, Ainscow and Denham 1984). Not 
only the extra volume but probably also the surface proper-
ties regarding bacterial adherence and colonization of the now 
inactive bone cement might reinforce this susceptibility (Oga 
et al. 1988). 
Strengths and limitations
One strength of our study was that it was based on a population 
of about 25 million inhabitants in 4 countries, with high com-
pleteness of data and coverage in the registries (Soderman et al. 
2000, Pedersen et al. 2004, Espehaug et al. 2006). The positive 
predictive value of the registered RA diagnosis is also high 
(Pedersen et al. 2004). Consequently, the population of THR 
patients was large, giving a large cohort of RA patients with 
THRs for the long-term evaluation of the rare prosthetic joint 
infections.                                                                                                                                         
Some limitations of the study must also be considered. We 
lack information on what medical treatment was used in the 
individual patient. We may only assume that patients in this 
study were treated in accordance with the recommendations 
for patients with RA at the time (Smolen et al. 2010b). In addi-
tion, the number of revisions for infection performed in RA 
patients was low (n = 87 in 13,384 RA patients), but even so, 
our material on hip replacements in RA patients is among the 
largest published. Another limitation is that in a recent study 
from the Swedish Hip Arthroplasty Register, the complete-
ness of reporting of early infection after THR was found to 
be 67% (Lindgren et al. 2014). However, we believe that the 
completeness of reporting is most likely the same for patients 
with different diagnoses. With the use of OA patients as con-
trols, a difference detected between the 2 patient groups can 
be considered reliable. We lacked information on comorbidity 
before THR, which is well known to differ between RA and 
OA patients, and may affect the risk of revision due to infec-
tion following THR (Rud-Sorensen et al. 2010). However, we 
have no reason to believe that this difference has changed over 
time. If there is any difference, we might expect a reduction in 
comorbidity with time in RA patients due to improved medi-
cal treatment. Finally, no information on antibiotic prophy-
laxis was included in the study. Such data have been shown to 
vary widely—within countries as well as between them. We 
cannot rule out the possibility of RA patients having different 
prophylactic antibiotic regimens from OA patients, although 
this is not the case in our department. 
In conclusion, we found a higher risk of revision caused by 
prosthetic joint infection in patients with RA than in those with 
OA. The difference was only present from 2002 onward. The 
increased risk of revision for infection in RA patients coin-
cided with a change in treatment strategy for these patients, 
with more aggressive immunmodulating therapy. For THRs 
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with antibiotic-loaded cement, a higher risk of very early and 
late infections leading to revision was seen in RA patients than 
in OA patients.
JCS, BTF, and AMF performed the analyses. JCS and BTF wrote the manu-
script. All the authors contributed to interpretation of the analyses and to criti-
cal revision of the manuscript.
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